About Us

The Company was founded by Ir. Sarkri Kosasih under the name PT Pyridam on November 27th, 1976 according to the Notarial Deed No. 31 dated November 27th, 1976 drawn up before Tan Thong Kie, Notary in Jakarta. At the early stage, the main activities of PT Pyridam were producing and marketing veterinary products. The marketing was done through sales agents in several major cities in Indonesia.

The Company diversified its business by producing and developing human medicines at the initial stage of its business expansion. In 1985, the Company was also honored by several overseas principals with marketing rights of their medical equipment products in territory of Indonesia, particularly in the laboratory apparatus/ equipment sector.

PT Pyridam Veteriner was established to stay focused on the veterinary product business while PT Pyridam focus on the business of human medicine and laboratory apparatus/equipment.

Company built a factory (production facility) located in Desa Cibodas, Puncak, West Java.

The Company's production factory started its operation. In the same year, the Company completed an Initial Public Offering (IPO) of 120,000,000 ordinary shares and was listed on the Jakarta Stock Exchange which later changed its name to Indonesia Stock Exchange (the "Company Initial Public Offering"). The Company name was changed from PT Pyridam into PT Pyridam Farma Tbk. for the Initial Public Offering of the Company's Shares based on the Deed of Minutes of the Company No. 267, dated December 23rd, 2000, drawn up before Tse Min Suhardi, S.H., Notary in Jakarta which has been approved by the Minister of Law and Human Rights of Republic of Indonesia based on Decree No. C-00321 HT.01.04.TH.2001, dated April 25, 2001 ("Deed No. 267/2000").

The Company distributed dividends in the form of shares proportionally to the shareholding ratio.

PT Pyridam Farma Tbk. started exporting to the Philippines. The Company increased its investment for the purpose to increase production capacity of M-150 energy drink in powder and other products, in collaboration with PT Osotspa ABC Indonesia.

In order to comply with Government regulations and the competent Authorities, in 2016, the Company has completed the preparation of Good Corporate Governance and uploaded it to the Company web page, which includes:

1. Guidelines for good corporate governance (GCG)
2. Board Manual
3. Code of Conduct
4. Risk management
5. Audit Committee Charter
6. Internal Audit Unit Charter

PT Pyridam Farma Tbk. distributed dividend in cash form at a value of Rp. 2.90 per share amounting to a total of Rp. 1.55 billion.

The Company distributed a dividend in the form of cash of Rp. 4.00 per share amounting in total of Rp. 2.14 billion.

On July 20th, 2020, shares of PT Pyridam Internasional are sold to Rejuve Global Investment Pte. Ltd totaling 254,736,579 shares or approximately 47.61% of the total issued and paid-up capital of the Company.

This change of ownership makes Rejuve Global Investment Pte. Ltd. as the controlling shareholder of the Company. This announcement of the Company's acquisition has been announced in the Harian Koran. Neraca on July 21, 2020 by Rejuve Global Investment Pte. Ltd.

Then, in 2020 as well, the Company relocated its head office to Sinarmas MSIG Tower 12th Floor, Jl. Jend. Sudirman No.Kav. 21, RT.10/RW.1, Kuningan, Karet, Kecamatan Setiabudi, Kota Jakarta Selatan, Jakarta 12920 Indonesia.

In this year the Company also invested 990 shares or about 99.00% shares in PYFA Health Singapore Pte. Ltd.

In this year, the Company also received the "Best of the Best Awards: The Top 50 Companies for 2020" from Forbes Indonesia, the Company is one of the 50 High Performing Public Listed Companies in Indonesia.

In early 2021, the Company issued a public offering of Obligasi I Pyridam Farma Tahun 2020 worth Rp. 300 billion, of which the bonds have been listed on Indonesia Stock Exchange on January 14, 2021.

In addition, in early 2021, the Company has established 4 (four) subsidiaries, namely PT Pyfa Medika Indonesia, PT Mega Inter Distrindo, PT Pyfa Investama Medika, and PT Pyfa Sehat Indonesia.

On December 28th, 2021, the Company acquired the shares of PT Holi Pharma (PT HP) and on December 30th, 2021, the Company increased the capital in PT HP so that the Company's share ownership in PT HP directly became 99.99% and indirectly became 100% through the share ownership in PT HP by PT Pyfa Sehat Indonesia by 0.01%.

This year, the Company received some awards, including Top 5 Performing Listed Companies: Top 5 Rising Company in the Pandemic Era from Investor Magazine, Indonesia Best Business Transformation 2022 from SWA Magazine, and Top 50 Best of The Best Public Listed Companies from Forbes Indonesia.

On February 25, 2022, the Company conducted a Continuing Public Offering of Obligasi Berkelanjutan | Pyridam Farma Tahap 1 Year 2022 with a Principal Amount of Rp.400,000,000,000. The target of the Sustainable Bond Funds raised is Rp.1,200,000,000,000.

In July 2022, the Company has carried out the acquisition of all shares of the company PT Ethica Industri Farmasi (PT EIF). The Company's share ownership in PT EIF directly becomes 99.99% and indirectly becomes 100% through the ownership of shares in PT EIF by PT PSI of 0.01%. In addition, PT PSI has also completed a transaction to acquire shares of Indopacific Health Technology Pte. Ltd. a limited liability company established under the laws of Singapore ("IHT") which resulted in PSI owning 6.76% of the issued and paid-up capital in IHT.